adavosertib: Clinical Trials

31 trials of adavosertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 8 active not recruiting, 6 terminated, 1 recruiting. 31 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 231Completed 15, Active not recruiting 8, Terminated 6, Recruiting 1, Withdrawn 1
Phase 15Completed 3, Recruiting 1, Terminated 1

Follow adavosertib: new trials by email Literature Review of adavosertib trials Research Report on adavosertib

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adavosertib and Gemcitabine in Advanced Pancreatic
Adavosertib, Gemcitabine - Pancreatic Cancer
Phase 2WithdrawnJames Cleary, MD, PhD2022-06-012022-06-14
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Adavosertib - Uterine Serous Carcinoma
Phase 2CompletedAstraZeneca1092020-11-302023-08-14
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
Adavosertib - Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)182019-01-292026-10-23
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Phase 2CompletedNational Cancer Institute (NCI)312019-01-162023-10-17
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Adavosertib, Olaparib, Ceralasertib - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center962018-12-072026-07-16
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
AZD1775 - Uterine Cancer
Phase 2Active not recruitingDana-Farber Cancer Institute492018-10-222026-09-28
Prostate Cancer Biomarker Enrichment and Treatment Selection
Adavosertib, Savolitinib, Darolutamide - Prostate Cancer
Phase 2Active not recruitingCanadian Cancer Trials Group2002018-08-012025-08-21
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). - Metastatic Triple Negative Breast Cancer
Phase 2Active not recruitingAstraZeneca2732018-03-072026-10-14
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q)
Phase 2CompletedMayo Clinic32017-05-052019-09-06
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
Adavosertib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)332017-03-242026-11-18
CISPLATIN + AZD-1775 In Breast Cancer
Cisplatin, AZD1775 - Triple-negative Metastatic Breast Cancer
Phase 2CompletedDana-Farber Cancer Institute342017-01-182021-11-23
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib - Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Phase 2CompletedAstraZeneca722016-11-282024-06-07
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
AZD1775 - Small Cell Lung Cancer
Phase 2TerminatedSamsung Medical Center72016-06-072018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
AZD1775 - Small Cell Lung Cancer
Phase 2CompletedSamsung Medical Center242015-12-012021-03-19
OLAParib COmbinations
AZD2281, AZD5363, AZD1775 - Cancer
Phase 2TerminatedJoseph Paul Eder672015-11-012022-12-28
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Carboplatin, Paclitaxel, AZD1775 - Lung Cancer
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute422015-10-132026-02-19
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Adavosertib, Paclitaxel, Carboplatin - Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Phase 2CompletedAstraZeneca952015-01-302023-10-03
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
AZD1775, paclitaxel - Advanced Gastric Adenocarcinoma
Phase 2CompletedSamsung Medical Center262015-01-142022-06-15

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Ovarian Neoplasms (4)  ·  Lung Neoplasms (3)  ·  Neoplasms (3)  ·  Carcinoma, Renal Cell (2)  ·  Fallopian Tube Neoplasms (2)  ·  Hematologic Neoplasms (2)  ·  Lymphoma (2)  ·  Multiple Myeloma (2)  ·  Pancreatic Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Uterine Cervical Neoplasms (2)  ·  Uterine Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Brenner Tumor (1)

Sponsors

National Cancer Institute (NCI) (9)  ·  AstraZeneca (6)  ·  Samsung Medical Center (3)  ·  Dana-Farber Cancer Institute (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Canadian Cancer Trials Group (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  James Cleary, MD, PhD (1)  ·  Joseph Paul Eder (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  The Netherlands Cancer Institute (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (20)  ·  Canada (7)  ·  Netherlands (4)  ·  South Korea (4)  ·  Spain (4)  ·  France (3)  ·  Italy (3)  ·  Germany (2)  ·  Poland (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Guam (1)  ·  Hungary (1)

Top investigators

David R Spigel, MD (2)  ·  A P Chen (1)  ·  Aaron Hansen (1)  ·  Amit M Oza (1)  ·  Andrew Tutt, MB ChB PhD (1)  ·  Birgit Geoerger, MD (1)  ·  Eric Winquist (1)  ·  FL Opdam, MD PhD (1)  ·  Haiyi Jiang, M.D. (1)  ·  James Cleary, MD, PhD (1)  ·  Jennifer R Eads (1)  ·  Jhanelle Gray, M.D. (1)  ·  Joseph P Eder, MD (1)

Results publications

PMID 41212474, PMID 26586415, PMID 26602013, PMID 27998224, PMID 31398082, PMID 31538815, PMID 32203306, PMID 32463741, PMID 33048619, PMID 33485453, PMID 33705205, PMID 33892407, PMID 34347542, PMID 34543871, PMID 34645648, PMID 34716177, PMID 34904813, PMID 35133871, PMID 35138919, PMID 35292802, PMID 36351402, PMID 36469840, PMID 37053535, PMID 37236033, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38920407, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40262070, PMID 40865033, PMID 41066729, PMID 41838385, PMID 42686334

NIH funding

U10CA180820 (3), 2016 (2), N01CM00032 (2), U24CA196172 (2), 2009 (1), 2015 (1), 2017 (1), N01CM00038 (1), N01CM00071 (1), P30CA015083 (1), U10CA021115 (1), U10CA180821 (1), UM1CA097452 (1), UM1CA186644 (1), UM1CA186688 (1)